Levofloxacin chemical structure
Find information on thousands of medical conditions and prescription drugs.

Levaquin

Levofloxacin is a fluoroquinolone antibiotic, marketed by Ortho-McNeil under the brand name Levaquin. Chemically, levofloxacin is the S-enantiomer (L-isomer) of ofloxacin. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
Labetalol
Lacrisert
Lactitol
Lactuca virosa
Lactulose
Lamictal
Lamisil
Lamivudine
Lamotrigine
Lanophyllin
Lansoprazole
Lantus
Lariam
Larotid
Lasix
Latanoprost
Lescol
Letrozole
Leucine
Leucovorin
Leukeran
Levaquin
Levetiracetam
Levitra
Levocabastine
Levocetirizine
Levodopa
Levofloxacin
Levomenol
Levomepromazine
Levonorgestrel
Levonorgestrel
Levophed
Levora
Levothyroxine sodium
Levoxyl
Levulan
Lexapro
Lexiva
Librium
Lidocaine
Lidopen
Linezolid
Liothyronine
Liothyronine Sodium
Lipidil
Lipitor
Lisinopril
Lithane
Lithobid
Lithonate
Lithostat
Lithotabs
Livostin
Lodine
Loestrin
Lomotil
Loperamide
Lopressor
Loracarbef
Loratadine
Loratadine
Lorazepam
Lortab
Losartan
Lotensin
Lotrel
Lotronex
Lotusate
Lovastatin
Lovenox
Loxapine
LSD
Ludiomil
Lufenuron
Lupron
Lutropin alfa
Luvox
Luxiq
Theophylline
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Levofloxacin is effective against a number of gram-positive and gram-negative bacteria. Because of its broad spectrum of action, levofloxacin is frequently prescribed empirically for a wide range of infections (e.g. pneumonia, urinary tract infection) before the specific causal organism is known. If the causal organism is identified, levofloxacin is sometimes discontinued and the patient may be switched to an antibiotic with a narrower spectrum

Gram-positive bacteria

  • Enterococcus faecalis (many strains are only moderately susceptible)
  • Staphylococcus aureus (methicillin-susceptible strains)
  • Staphylococcus epidermidis (methicillin-susceptible strains)
  • Staphylococcus saprophyticus
  • Streptococcus pneumoniae (including penicillin-resistant strains*)
  • Streptococcus pyogenes

Levofloxacin only has moderate Gram-positive coverage; beta-lactams (e.g. ceftriaxone) or glycopeptides (e.g. vancomycin) are generally preferred for this indication.

Gram-negative bacteria

  • Enterobacter cloacae
  • Klebsiella pneumoniae
  • Pseudomonas aeruginosa
  • Escherichia coli
  • Legionella pneumophila
  • Serratia marcescens
  • Haemophilus influenzae
  • Moraxella catarrhalis
  • Haemophilus parainfluenzae
  • Proteus mirabilis
  • Campylobacter

Other

  • Chlamydia pneumoniae
  • Mycoplasma pneumoniae

Some information extracted from Levaquin Prescribing information.

Read more at Wikipedia.org


[List your site here Free!]


Outpatient treatment for low-risk pneumonia is safe
From American Family Physician, 11/1/05 by Kenneth W. Lin

Hospitalization rates for patients with community-acquired pneumonia vary widely. A clinical prediction rule based on the Pneumonia Severity Index (PSI) attempts to standardize care by grouping patients standardize care by grouping patients into five risk categories based on predicted 30-day mortality. General agreement exists that patients in high-risk classes IV and V should receive inpatient treatment. However, controversy remains regarding the optimal treatment setting for patients in lower-risk classes II and III, who account for up to one half of all hospitalizations. Carratala and colleagues conducted a randomized controlled trial to compare outcomes of inpatient and outpatient treatment of patients in PSI risk classes II and III.

The study population consisted of 224 patients who were at least 18 years of age and had received a diagnosis of community-acquired pneumonia (PSI class II or III) in the emergency departments of two tertiary care hospitals. Patients were excluded from the study if they were hypoxic, immuno-suppressed, or had a serious comorbid medical or psychosocial condition that mandated hospitalization. Patients also were excluded if they had received a quinolone antibiotic in the preceding three months or had a known allergy or other contraindication (such as pregnancy or breastfeeding) to quinolones. Following the collection of blood, sputum, and urine cultures, patients were randomly assigned to receive outpatient oral levofloxacin (Levaquin) 500 mg per day, or inpatient sequential intravenous and oral levofloxacin 500 mg per day.

All patients were reevaluated in the outpatient clinic at seven and 30 days after diagnosis. The primary endpoint was an overall successful outcome, defined as meeting seven predefined criteria (see accompanying table). Secondary endpoints were health-related quality of life and satisfaction with care, assessed with standardized questionnaires. Of the 224 patients originally enrolled, 203 completed the study protocol.

An overall successful outcome was recorded at the 30-day visit in 83.6 percent of outpatients and 80.7 percent of initially hospitalized patients. The one patient who died had received outpatient treatment and was hospitalized for intestinal ischemia two weeks after being diagnosed with pneumonia. Health-related quality of life was similar between groups, but outpatients reported greater satisfaction with their care than did inpatients (91.2 versus 79.1 percent).

The authors conclude that most patients in PSI classes II and III may be treated safely as outpatients, and that this treatment strategy improves patient satisfaction with care. In addition, they suggest that implementing this standard of care could produce significant economic savings because inpatient pneumonia treatment in the United States costs $6,000 to $7,000, whereas outpatient treatment costs less than $200. They caution, however, that this small study of low-risk patients was not powered to detect a difference in mortality.

Criteria for an Overall Successful Outcome

Clinical and radiographic resolution of pneumonia *

Absence of adverse drug reactions

Absence of medical complications during treatment

No need for additional hospital visits

No changes in initial antibiotic regimen with levofloxacin (Levaquin)

No subsequent hospital admission within 30 days of diagnosis

Absence of death from any cause within 30 days of diagnosis

*--Pneumonia was considered cured when all baseline signs (fever, hypothermia, altered breath sounds) and symptoms (cough, chest pain, dyspnea) resolved and infiltrates were no longer seen on chest radiography.

KENNETH W. LIN, M.D.

Carratala J, et al. Outpatient care compared with hospitalization for community-acquired pneumonia. A randomized trial in low-risk patients. Ann Intern Med February 1, 2005;142:165-72.

COPYRIGHT 2005 American Academy of Family Physicians
COPYRIGHT 2005 Gale Group

Return to Levaquin
Home Contact Resources Exchange Links ebay